Awalpreet S Chadha1, Jillian R Gunther1, Cheng-En Hsieh2, Maureen Aliru1, Lakshmi S Mahadevan1, Bhanu P Venkatesulu1, Christopher H Crane3, Prajnan Das1, Joseph M Herman1, Eugene J Koay1, Cullen Taniguchi1, Emma B Holliday1, Bruce D Minsky1, Yelin Suh4, Peter Park4, Gabriel Sawakuchi4, Sam Beddar4, Bruno C Odisio5, Sanjay Gupta5, Evelyne Loyer6, Harmeet Kaur6, Kanwal Raghav7, Milind M Javle7, Ahmed O Kaseb7, Sunil Krishnan8. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States; Department of Radiation Oncology, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan, Taiwan. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. 4. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, United States. 5. Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, United States. 6. Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, United States. 7. Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. 8. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address: skrishnan@mdanderson.org.
Abstract
BACKGROUND AND PURPOSE: This study documents the utilization and efficacy of proton beam therapy (PBT) in western patients with localized unresectable hepatocellular carcinoma (HCC). METHODS AND METHODS: Forty-six patients with HCC, Child-Pugh class of A or B, no prior radiotherapy history, and ECOG performance status 0-2 received PBT at our institution from 2007 to 2016. Radiographic control within the PBT field (local control, LC) and overall survival (OS) were calculated from the start of PBT. RESULTS: Most (83%) patients had Child-Pugh class A. Median tumor size was 6 cm (range, 1.5-21.0 cm); 22% of patients had multiple tumors and 28% had tumor vascular thrombosis. Twenty-five (54%) patients received prior treatment. Median biologically effective dose (BED) was 97.7 GyE (range, 33.6-144 GyE) administered in 15 fractions. Actuarial 2-year LC and OS rates were 81% and 62% respectively; median OS was 30.7 months. Out-of-field intrahepatic failure was the most common site of disease progression. Patients receiving BED ≥90 GyE had a significantly better OS than those receiving BED <90 GyE (49.9 vs. 15.8 months, p = 0.037). A trend toward 2-year LC improvement was observed in patients receiving BED ≥90 GyE compared with those receiving BED <90 GyE (92% vs. 63%, p = 0.096). On multivariate analysis, higher BED (p = 0.023; hazard ratio = 0.308) significantly predicted improved OS. Six (13%) patients experienced acute grade 3 toxicity. CONCLUSIONS: High-dose PBT is associated with high rates of LC and OS for unresectable HCC. Dose escalation may further improve outcomes.
BACKGROUND AND PURPOSE: This study documents the utilization and efficacy of proton beam therapy (PBT) in western patients with localized unresectable hepatocellular carcinoma (HCC). METHODS AND METHODS: Forty-six patients with HCC, Child-Pugh class of A or B, no prior radiotherapy history, and ECOG performance status 0-2 received PBT at our institution from 2007 to 2016. Radiographic control within the PBT field (local control, LC) and overall survival (OS) were calculated from the start of PBT. RESULTS: Most (83%) patients had Child-Pugh class A. Median tumor size was 6 cm (range, 1.5-21.0 cm); 22% of patients had multiple tumors and 28% had tumor vascular thrombosis. Twenty-five (54%) patients received prior treatment. Median biologically effective dose (BED) was 97.7 GyE (range, 33.6-144 GyE) administered in 15 fractions. Actuarial 2-year LC and OS rates were 81% and 62% respectively; median OS was 30.7 months. Out-of-field intrahepatic failure was the most common site of disease progression. Patients receiving BED ≥90 GyE had a significantly better OS than those receiving BED <90 GyE (49.9 vs. 15.8 months, p = 0.037). A trend toward 2-year LC improvement was observed in patients receiving BED ≥90 GyE compared with those receiving BED <90 GyE (92% vs. 63%, p = 0.096). On multivariate analysis, higher BED (p = 0.023; hazard ratio = 0.308) significantly predicted improved OS. Six (13%) patients experienced acute grade 3 toxicity. CONCLUSIONS: High-dose PBT is associated with high rates of LC and OS for unresectable HCC. Dose escalation may further improve outcomes.
Authors: Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Alexis Bujold; Christine A Massey; John J Kim; James Brierley; Charles Cho; Rebecca K S Wong; Rob E Dinniwell; Zahra Kassam; Jolie Ringash; Bernard Cummings; Jenna Sykes; Morris Sherman; Jennifer J Knox; Laura A Dawson Journal: J Clin Oncol Date: 2013-04-01 Impact factor: 44.544
Authors: Sunil Krishnan; Awalpreet S Chadha; Yelin Suh; Hsiang-Chun Chen; Arvind Rao; Prajnan Das; Bruce D Minsky; Usama Mahmood; Marc E Delclos; Gabriel O Sawakuchi; Sam Beddar; Matthew H Katz; Jason B Fleming; Milind M Javle; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-11 Impact factor: 7.038
Authors: Jennifer Pursley; Issam El Naqa; Nina N Sanford; Bridget Noe; Jennifer Y Wo; Christine E Eyler; Matthew Hwang; Kristy K Brock; Beow Y Yeap; John A Wolfgang; Theodore S Hong; Clemens Grassberger Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-27 Impact factor: 7.038
Authors: Ronik S Bhangoo; Trey C Mullikin; Jonathan B Ashman; Tiffany W Cheng; Michael A Golafshar; Todd A DeWees; Jedediah E Johnson; Satomi Shiraishi; Wei Liu; Yanle Hu; Kenneth W Merrell; Michael G Haddock; Sunil Krishnan; William G Rule; Terence T Sio; Christopher L Hallemeier Journal: Adv Radiat Oncol Date: 2021-03-02
Authors: Jana M Kobeissi; Lara Hilal; Charles B Simone; Haibo Lin; Christopher H Crane; Carla Hajj Journal: Cancers (Basel) Date: 2022-06-12 Impact factor: 6.575